- Home
- CMBM vs TCRX Comparison
CMBM vs TCRX Comparison
Compare CMBM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 64.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMBM | TCRX |
|---|---|---|
| Price | $1.62 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.5M | 755.6K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,215,000.00 | $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.88 |
| 52 Week High | $6.80 | $3.43 |
Technical Indicators
Market Signals| Indicator | CMBM | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 34.67 |
| Support Level | $1.41 | $0.99 |
| Resistance Level | $1.69 | $0.99 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 27.45 | 8.88 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.